Navigation Links
BioInformatics, LLC Studies Effective Strategies for Scientific Publishing in a Web 2.0 World
Date:12/1/2008

ARLINGTON, Va., Dec. 1 /PRNewswire/ -- BioInformatics, LLC (http://www.gene2drug.com) -- the leading market research and consulting firm serving the life science industry -- announces the publication of its latest report, "The Brave New World of Scientific Publishing." Going beyond the original social media study published jointly in 2007 by BioInformatics and PJA -- an award-winning business-to-business advertising and marketing agency -- this report explores the impact of Web 2.0 and Social Media applications on traditional publishing methodologies, and provides insight on how to best embrace this new industry standard to maintain a leadership role within the scientific community.

An in-depth analysis of the opinions of over 1,500 life scientists, this report uncovers key findings about how scientists rely on the Web for research, collaboration and networking. Discussion boards, blogs, wikis video and podcasts -- scientists are learning how to employ Web 2.0 and social media tools to good effect. Additionally, the report indicates that reliance on traditional media as an information source is waning, while online collaborative tools are becoming increasingly valuable to today's researcher.

A North American Lab Director had this to say: "The traditional peer review system is too slow, outdated, becoming obsolete... articles should be published right away on the net, linked by aggregator sites so other scientists can review and post comments online. This would open peer review to a much wider audience (hundreds can comment instead of 3-4) and should improve the quality of science."

Findings reveal that traditional publishing models, while still viable, no longer stand alone as a way to thrive in a community of scientists who want more speed, more control and easier access to information than ever before. Plus, scientists want to be heard. Publishers that understand this -- and adapt -- are already taking the lead.

"Our assessment is that publishers are well-placed to deliver social tools in a secure and trusted environment, but they also need to innovate tools that are more relevant, focused and easy to use," observes noted science writer Richard Grant, who served as a lead consultant on the report.

The time for "wait and see" is past; The Brave New World of Scientific Publishing provides the advantage required to anticipate and deliver on the needs of the modern scientist. "An organization must leverage its existing reputation to join -- and influence -- the online dialogue," notes Dr. Tamara Zemlo, Director of Syndicated Research and Analysis for BioInformatics, LLC. This report is a must-read for any company looking to remain competitive within the rapidly evolving scientific community.

The Brave New World of Scientific Publishing is based on 1,557 responses to a 37 question online survey fielded to The Science Advisory Board in May 2008. BioInformatics LLC sponsors this global online community of more than 40,000 scientists, physicians and healthcare professionals.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 40,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    To purchase this report or for additional information, please contact:

    Mary Follin
    Director of Communications
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13 (phone)
    m.follin@gene2drug.com
   http://www.gene2drug.com/

'/>"/>
SOURCE BioInformatics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts
2. Sigma-Aldrich Recognized by BioInformatics, LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs
3. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
4. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
5. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
8. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
9. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
10. ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
11. Five New Clinical Studies Show Value of Masimo PVI & PI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... -- In today,s pre-market research, Stock-Callers.com directs ... (NYSE: XON), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and Concordia ... article on Barron,s, Credit Suisse upgraded its rating on the ... st , 2017. These stocks research reports can be downloaded ... ...
(Date:3/29/2017)... ... 2017 , ... Zansors announced today its first utility patent ... U.S. Patent & Trademark Office (USPTO). The patent covers a wearable patch with ... invention will be critical to the future of wearable tech for health applications. ...
(Date:3/29/2017)... KING OF PRUSSIA, Pa. , March 29, 2017 ... access to care, which is why CSL Behring awards ... advocacy work of rare disease patient groups. These groups ... patients, voices are heard on Capitol Hill and in ... current funding cycle, the community-based grant was awarded to ...
(Date:3/29/2017)... Germany , March 29, 2017 QIAGEN N.V. (NASDAQ: ... QIA) today announced the U.S. launch of its ipsogen ® ... the U.S. Food and Drug Administration as a qualitative in vitro diagnostic test ... EDTA whole blood.* ... JAK2 assay is processed on QIAGEN,s Rotor-Gene ® Q MDx system, which ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
Breaking Biology News(10 mins):